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Abstract  
 This study proposes a strategy, based on the Self-regulation Therapy, to change 
personality and its biological substrate, the DRD3 gene expression. It has been 
demonstrated that acute doses of stimulating drugs, like methylphenidate, are able to 
change personality and the expression of certain genes in the short term. On the other 
hand, the Self-regulation Therapy has been proved to reproduce the effects of drugs. 
Thus, it is feasible to hope that the Self-regulation Therapy is equally effective to 
change personality and the gene expression as methylphenidate. This is a preliminary 
study with a single case experimental design with replication in which two subjects 
participate. The results and potential implications for research and psychotherapy are 
discussed. 
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Introduction  
 Since Pavlov’s experiment on conditioning drug effects (1927), drug-associated 
conditioning responses have been well-established (Lynch, Stein & Fertziger, 1976; 
O’Brien, Childress, McLellan & Ehrman, 1992; Stewart, deWit & Eikelboom, 1984).  
If we take the drug as being the US (unconditioned stimulus) and the 
reproduction of its effects the CR (conditioned response), when repeatedly matching the 
US and a CS (conditioned stimulus, neutral), the latter will be able to elicit the CR in 
the absence of the drug. 
As regards abuse drugs, there is experimental evidence in humans for 
conditioning responses similarly to heroin (Blachley, 1971; Levine, 1974; O´Brien, 
1975; O´Brien, Ehrman & Ternes, 1986; Solé, 1983). These studies show the already 
classic “fantasy of the needle” phenomenon (Levine, 1974) which is characterized by 
the appearance of sensations of euphoria and well-being in response to the self-
administration of a pharmacologically inert substance, such as saline solution. Subjects 
can feel subjective sensations (well-being, “getting high”) and physiological changes 
(constriction of pupils) in response to an injection of saline solution (O´Brien, 1975; 
O´Brien, Nace, Mintz, Meyers & Ream, 1980; O´Brien et al., 1986). The similar 
conditioned effects to those of drugs will become greater if subjects inject saline 
solution into the habitual places of consumption where they hope “to get high” 
(O´Brien, Childress, McLellan & Ehrman, 1993). 
On the other hand, conditioning the effects of cocaine has been verified in 
animals (Barr et al., 1983; Post, Lockfeld, Squillage & Contel, 1981) and humans 
(Muntaner et al., 1989). In humans, the power of verbal instructions to elicit the effects 
of a previous cocaine intake experience has been demonstrated. Not only can a certain 
stimulus elicit the effects of drugs, but the context and the atmosphere (room, people, 
drug injection ritual) can also act as elements of a complex conditional stimulus which, 
when repeatedly connected with a cocaine injection, will elicit similar conditioned 
placebo responses to those produced by the drug (O'Brian et al., 1986). 
In addition to classic conditioning, attempts have been made in which subjects 
experience the sensations of the drug by means of suggestion. Pavlov previously stated 
that: “suggestion is the simpler and typical conditioned reflex of the human being”. 
Thus, it has been ascertained that users and non users of drugs experience the effects of 
a wide variety of drugs, like cannabis, barbiturates, ecstasy, amphetamines or LSD, by 
means of suggestion (Bauman, 1971; Fogel & Hoffer, 1962; Granone, 1973; Hastings, 
2006). 
 
 Besides, there is evidence for a conditioned gene expression elicited by drug-
associated environmental cues. A marked up-regulation of the expression of the 
immediate early gene product Fos has been found during exposure to a morphine-paired 
environment (Schroeder, Holahan, Landy & Kelley, 2000) or to a cocaine-paired 
environment (Brown, Robertson & Fibiger, 1992; Neisewander et al., 2000). 
Furthermore, the same mechanism has been observed to up-regulate the arc during 
exposure to a nicotine-paired environment (Schiltz, Kelley & Landry, 2005).   
 In order to increase the therapeutic efficacy of the conditioning mechanism and 
suggestion, the Self-regulation Therapy was created (Amigó, 1992). This procedure is a 
therapeutic suggestion technique deriving from the cognitive-behavioral approach to 
hypnosis (Spanos & Chaves, 1989). It uses direct suggestions without any formal 
hypnosis induction procedure, but introduces suggestions through normal conversation 
with the subject fully awake and conscious. The Self-regulation Therapy has proved 
effective for smoking reduction (Bayot, Capafons & Cardeña, 1997; Capafons & 
The Self-regulation Therapy to reproduce drug effects 
 
Amigó, 1995) and for reproducing (conditioning) drug effects, ranging from heroin 
(Amigó, 1998) to stimulants such as ephedrine (Amigó, 1994) or methylphenidate 
(Amigó, 1997). The Self-regulation Therapy has been described elsewhere (for instance, 
Amigó, 1994; 1998). Next we present a brief description of this therapy. 
The Self-regulation Therapy is comprised of three phases. In the first phase, 
several sensory recall exercises are used to teach subjects how to voluntarily reproduce 
various physical sensations (salivation, leg paralysis, arm heaviness and hand rigidity) 
which are initially provoked by real stimuli. Subjects are asked to associate these 
sensations with images, words or other cues that will help them to later reproduce the 
sensations without the physical stimuli. 
 In the second phase, subjects reproduce these sensations several times without 
the physical stimuli for the purpose of making the response quicker and clearer in each 
trial. At the end of the second phase, the use of images and other cues is faded so that a 
direct suggestion suffices to produce a sensation with the feeling of automaticity. 
 In the last phase, also called the “generalization phase”, demand of any kind 
generates the suggested effects. At the beginning of the phase, subjects are told that as 
they have performed exercises previously, their minds are highly activated and 
receptive, so they can respond to the therapist’s verbal suggestions without having to be 
trained for each new session. At this point, patients are provided with therapeutic 
suggestions or drug reproduction suggestions. In subsequent sessions, the first and 
second phases are shortened, or even omitted altogether. 
 Acute administration of psycho-stimulants, such as cocaine or methylphenidate, 
brings about changes in the gene expression (Berke, Paletzki, Aronson, Hyman & 
Gerfen, 1998; Torres & Rivier, 1994; Yano & Steiner, 2005). The D3 dopamine 
receptor is one of the three of the D2 subtype, these being D2, D3 and D4. The D1 
dopamine receptor subtype exists, as does D5. All these mRNA dopamine receptors 
have been found in human peripheral blood lymphocytes (Ostadali et al., 2004; Ricci et 
al., 1999; Takahashi, Nagai, Ueno, Saeki & Yanagihara, 1992). 
 The D3 dopamine receptor shows a high affinity for dopamine (Strange, 1993), 
is preferentially localized in the mesocortical-limbic dopamine system and projects to 
the ventral striatum (Levant, 1998; Suzuki, Hurd, Sokoloff, Schwartz & Sedvall, 1998). 
Thus, DRD3 is considered to play a major role in cognition and emotion (Meador-
Wooddruff, Mansour, Saul & Watson, 1994), in neuropsychiatric diseases (Levant, 
1997) and in personality (Czermak et al., 2004).  
 Furthermore, there is evidence that DRD3 plays a role in addiction mechanisms, 
such as drug-seeking and drug-taking behavior (Caine & Koob, 1993; Pilla et al., 1999). 
These authors reported that D3-selective agonists provoke reductions in cocaine reward 
and seeking. However, similar effects have been reported with a potent, highly selective 
D3 antagonist (Vorel et al., 2002). Hence, the results are variable and contradictory. Yet 
it is possible that the putative D3 agonists used in previous studies do not possess full 
D3 agonist properties (Levant, 1997). It is also possible that they are partially agonist or 
mixed D3 agonists/antagonists, and that they are predominant antagonist properties. On 
the other hand, D3-preferring antagonist nafadotride produces biphasic effects on 
locomotive activity in rats by stimulating locomotion at lower doses and inhibiting 
locomotion at higher doses (Sautel et al., 1995). The nafadotride doses which increase 
locomotive activity produce D2 receptors occupancy; whereas those that inhibit 
locomotion generate significant D3 occupancy. On the other hand, D3-preferring 
agonist 7-OH-DPAT produces not only inhibitory effects at lower doses, which are 
attributed to DRD3, but also stimulatory effects at higher doses, which are attributed to 
DRD2 (Daly & Walington, 1993). There is also evidence that the blockage of DRD3 
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reduces c-fos (Merchant, Figur & Evans, 1996). In our study, it is possible that the 
dopamine level is not high enough during the first hour, and that the dopamine level is 
higher during the second or third hour.  
 It is also feasible that a dynamic study into the variation of DRD3 mRNA can 
prove useful in our understanding of its mechanism of action. At present however, the 
direct assessment of human brain changes in DRD3 mRNA is not possible. The 
“peripheral marker hypothesis” asserts that the expression of the dopamine receptors in 
peripheral blood lymphocytes (PBL) reflects their expression in the brain. Kwak, Koo, 
Choi and Sunwoo (2001) measured the changes of the DRD3 mRNA expression in 
lymphocytes of schizophrenic patients after they took antipsychotics. After taking 
medication, DRD3 mRNA peaked at the 2nd week to later decrease, but the level was 
above baseline one at 8th week.   
 The findings of Kwak et al. (2001) reveal the reactivity of DRD3 mRNA to 
drugs. Nevertheless, no study into the reactivity of the DRD3 mRNA expression in 
human lymphocytes deriving from an acute administration of a stimulant drug has been 
found. 
According to the “peripheral marker hypothesis”, the expression of the 
dopamine receptors in peripheral blood lymphocytes (PBL) reflects their expression in 
the brain. There is accumulative evidence for an altered neurotransmitter receptor 
expression in the PBL of patients with neuropsychiatric disorders. For example in 
relation to the D3 dopamine receptor, a reduced mRNA expression of the DRD3 in PBL 
was found in patients with Parkinson’s disease which correlated with clinical severity 
(Nagai et al., 1996). Moreover, a reduced PBL expression of DRD3 in patients with 
Alzheimer’s disease has been reported (Barbanti et al., 2000a). Nevertheless, an 
increased PBL expression of DRD3, DRD4 (Barbanti et al., 2000b) and DRD5 (Barbanti 
et al., 1996) was found in migraine patients. An elevated dopamine receptor D3 mRNA 
in the PBL of patients with schizophrenia has also been reported (Illani et al., 2001), 
which also correlates with clinical severity and reacted sensitively to the administration 
of antipsychotics (Kwak et al., 2001). 
 The dopaminergic system has been implicated in personality traits in healthy 
individuals (Comings et al., 2000). There is a negative correlation between the DRD3 
mRNA expression in PBL and the persistence trait (Czermak et al., 2004). Nevertheless, 
the temporary dynamics of gene expression and personality has not yet been studied. It 
is possible that DRD3 is related to inhibiting mechanisms of personality. Accili et al. 
(1996) encountered increased locomotive activity and rearing behavior and 
hyperactivity in one strain of D3 “knock-out” mice in an exploratory test. Some 
evidence suggests that DRD3 activation inhibits the mesocorticolimbic DA function 
(Gilbert, Millar & Cooper, 1995; Lejeune & Millan, 1995) and that DRD3 inhibition 
actives the mesocorticolimbic DA system (Nissbrant, Ekman, Eriksson & Heilig, 1995). 
Czermak et al. (2004) explained how the DRD3 expression level accounts for the 
dopamine release pattern. Thus, a reduced pre-synaptic self-receptor function enhances 
tonic dopamine release. Furthermore, the D3 receptor inhibits dopamine release (Tang, 
Todd & O’Malley, 1994). On the other hand, a low postsynaptic expression reduces 
phasic dopaminergic neurotransmission in the prefrontal cortex.  
A dynamic mathematical model has been proposed to explain short-term 
personality changes caused by an acute administration of psycho-stimulants such as 
cocaine (Amigó, Caselles & Micó, 2008a; Caselles, Micó & Amigó, 2011) using a 
personality adjectives scale. Besides, a dynamical model of personality and gene 
expression changes produced by caffeine has been proposed (Amigó, Caselles & Micó, 
2008b). In addition, the Self-regulation Therapy has reproduced the dynamics of the 
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effect of methylphenidate on the pattern of change in the glutamate concentration in 
blood and of the general factor of personality scores (Amigó, Caselles, Micó & García, 
2009). 
In this study, we analyze the personality and gene expression changes (DRD3 
mRNA gene) deriving from an acute administration of methylphenidate and a 
psychological suggestion technique to reproduce drug effects. Two voluntary subjects 
participated in this study. A single case experimental design with replication to control 
the considered variables is proposed. Both subjects took a dose of methylphenidate and 
the pattern of change in the gene expression of DRD3 and in personality was recorded. 
The mRNA expression of DRD3 was measured in peripheral blood lymphocytes. 
Personality was measured by the Big Five Personality Adjectives List (BFPAL) (Brody 
& Ehrlichman, 1998). Schutte, Malouff, Segrera, Wolf and Rodgers (2003) devised the 
Big Five States Inventory by starting with the hierarchical model of personality. Traits 
are conceptualized as a higher level with enduring characteristics, while states are a 
lower level with less enduring characteristics (p. 592). These authors did a confirmatory 
factor analysis (CFA) to show an acceptable degree of fit between the responses in the 
transitory states measurements and the Big Five dimensions. We also measured the Big 
Five in a state-format version, but with another adjective list, the BFPAL. One of the 
subjects applied the Self-regulation Therapy to reproduce the short-term change patterns 
in personality and gene expression which methylphenidate produced. 
Indeed, we herein propose that the Self-regulation Therapy changes personality 
measured by BFPAL, as it does with methylphenidate, and that it also modifies the 
DRD3 mRNA levels dynamically. 
 
Materials and Methods 
A single case experimental design.  
a) Subjects. 
 Two male subjects, aged 45 and 46 years, participated in the experiment as two 
University staff volunteers. 
b) Instruments. 
 The Big Five Personality Adjectives List (BFPAL) (Brody and Ehrlichman, 
1998). This list is made up of 25 adjectives. A state-format version (“Are you 
like this at the moment?” was used. Both subjects completed the state-format 
version every 15 minutes to obtain a situational measure of the BFPAL. 
 Biological analysis. First, blood samples were taken and lymphocytes were 
isolated by density centrifugation in Lymphoprep. Second, an automated mass 
spectrometry platform (Sequenom, MassARRAY Quantitative Gene 
Expression) was used for the quantification of the DRD3 mRNA concentration in 
lymphocytes. -actin was used as an internal RNA standard. 
c) Procedure and experimental design. 
 One experiment was done per subject. The experimental design for Subject 1 was 
ABC and ABAD for Subject 2. Both experiments were a partial replication of each 
other, where two experimental conditions agreed: A and B. For Subject 2, an 
experiment with replication was considered to be intra-subject since AB was 
replicated by AD, although conditions B and D were not exactly the same ones. As 
seen, and when the experimental design is complex, we go on to present it in detail: 
 Subject 1 filled in the BFPAL form every 15 minutes (17 records per phase) 
in all these phases and blood samples were taken once per hour (five 
samples per phase).  
 Phase A is the baseline, without treatment.  
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 In phase B, the subject took a 20 mg dose of methylphenidate 
immediately after completing the first BFPAL form. At the same time, 
the first blood sample was taken. Next, the subject completed 16 BFPAL 
forms, one every 15 minutes, and a blood sample was taken once per 
hour during 4 hours.  
 In phase C, the subject took 40 mg of methylphenidate immediately 
after completing the first BFPAL form. Next, the first blood sample was 
taken. As in phase A, the subjects filled in 16 BFPAL forms, one every 
15 minutes. A blood sample was taken each hour during 4 hours after 
filling in the corresponding BFPAL form.  
 
The sequence of the experiment for Subject 1 was: 
o Day 1: the experimental subjects went to the medical laboratory. Phase 
A: baseline.  
o Day 2: the subjects took 20 mg of methylphenidate. Phase B. 
o Day 3: Subject 1 took 40 mg of methylphenidate. Phase C.  
 
 Subject 2 followed the same procedure as Subject 1 in Phases A and B. On 
day 3, there were two experimental conditions: 1) baseline (A) for one hour 
and 45 minutes, and 2) after the second hour, the subject applied the Self-
regulation Therapy to reproduce the drug effects obtained in Phase B (D). 
The BFPAL register and the blood samples were obtained following the 
same protocol as in the previous phases.  
Thus for Subject 2, there were a control condition (the first 7 points) and 
an experimental condition (the Self-regulation Therapy, 9 points). We can 
state that the experimental design for Subject 2 was ABAD: A (baseline 1), 
B (20 mg methylphenidate), A (baseline 2), and D (the Self-regulation 
Therapy). 
Besides following the sequence of the experiment described in the 
previous section, Subject 2 participated in three Self-regulation Therapy 
training sessions: one session with a 20 mg administration of 
methylphenidate and three sessions in which the effects of the drug were 
reproduced with the Self-regulation Therapy. 
The sequence of the experiment for Subject 2 was: 
1) Phase A, baseline. The BFPAL scores were recorded and blood samples 
were taken.   
2) Phase B, 2 weeks later. Intake of 20 mg of methylphenidate; the BFPAL 
scores were recorded and blood samples were taken.   
3) Phase R1, 2 days later. The effects of the drug were reproduced with the 
Self-regulation Therapy and the BFPAL scores were recorded.   
4) Phase B2, 1 week later. Intake of 20 mg of methylphenidate and the 
BFPAL scores were recorded.   
5) Phase R2, 2 days later. The effects of the drug were reproduced with the 
Self-regulation Therapy and the BFPAL scores were recorded.   
6) Phase D, 1 week later. In which the effects of the drug were reproduced 
with the Self-regulation Therapy, the BFPAL scores were recorded and 
blood samples were taken. 
 
 Thus, we can see that the sequence of the experiment for Subject 2 coincides 
with that of Subject 1 in Phases A and B. Also for Subject 2, three training sessions took 
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place between Phases B and D, of which two were to reproduce the drug effects with the 
Self-regulation Therapy (R1 and R2) and one session involved the intake of 20 mg of 
methylphenidate (B2). 
 In sessions B2, R1 and R2, blood extractions were not taken, but the subjective 
activation was recorded using the BFPAL. Sessions R1 and R2 were replication sessions 
involving the reproduction of the subjective effects of the drug with the Self-regulation 
Therapy and, simultaneously, they served as training sessions. 
 During Phase D, the Self-regulation Therapy was applied 1 hour and 45 minutes 
after beginning the session. This time prior to applying the Self-regulation Therapy 
constitutes an intra-session baseline. 
 Both subjects took 20 mg of methylphenidate in Phase B. A literature review of 
the effect of different oral doses of methylphenidate (Kollins, MacDonald & Rush, 
2001) shows that, depending on the experimental context, doses from 10-40 mg can 
cause clear subjective effects. Yet in the research into the acute effects of oral 
methylphenidate doses, the standard amount of 20 mg has been used on many occasions 
(Volkow, Wang, Fowler, Telang et al., 2004; Volkow, Wang, Telang, Fowler et al., 
2008). On the other hand, some studies have considered that the therapeutic 
methylphenidate dose should be between 0.3 mg/kg and 0.6 mg/kg (Volkow, Wang, 
Fowler, Gatley & Logan, 1998). 
  If we take this into account, the methylphenidate dose in Phase B was infra-
therapeutic in both cases. Thus for Subject 1, whose weight was 86 kg, the therapeutic 
dose oscillated between 25.8 mg and 51.6 mg, whereas for Subject 2, who weighed 75 
kg, the therapeutic dose ranged between 22.5 mg and 45 mg. However, Subject 1 took 
40 mg in Phase C, which is indeed a therapeutic dose. 
  In order to verify the effectiveness of the Self-regulation Therapy to reproduce 
the effect of the drug, we designed a complex single case experiment in which several 
controls have been set out for this very purpose. Thus, it is possible to compare the Self-
regulation Therapy training sessions (R1 and R2) with their respective 20 mg 
methylphenidate intake sessions (B and B2). 
 This reveals the complexity and goodness of the single case experimental design 
with replication which we have used. Next, we present some relevant results of the 
many results that can be obtained. 
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Figure 1. BFPAL registers (points) for subject 1 for phases A, B and C.  
E: Extraversion; N: Neuroticism; A: Agreeableness, R: Responsibility; O: Openness. 
 
 
Results 
 Figure 1 presents the graph of Subject 1’s BFPAL score records for the three 
phases (separated by a space): A (baseline), B (20 mg methylphenidate) and C (40 mg 
methylphenidate). A very clear difference between the baseline record and the record 
with the two methylphenidate intake conditions was observed. In the first case 
(baseline), no pattern was observed in the Big Five factors scores. In Phase B (20 mg), 
an inverted U shape was observed for the scores of all the factors, although it was less 
intense for Neuroticism. In Phase C (40 mg), the effect was particularly lower than with 
20 mg, but the pattern was the same, an inverted U shape, for the Big Five factors 
scores (Extraversion, Neuroticism, Agreeableness, Responsibility and Opening). 
 These results indicate that the Big Five factors tend to change simultaneously 
and that 40 mg produces, in this subject, a slighter subjective effect than the effect of 20 
mg, which indicates a possible effect of habituation or transmarginal inhibition. 
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Figure 2. BFPAL registers (points) for subject 2 for phases R1, R2 and D.  
E: Extraversion; N: Neuroticism; A: Agreeableness; R: Responsibility; O: Openness. 
 
 Figure 2 offers the graph of Subject 2’s BFPAL score records for the three Self-
regulation Therapy sessions: R1, R2 and D. A very similar pattern of change in the three 
sessions was observed: an inverted U for the Extraversion, Agreeableness, 
Responsibility and Opening factors, and a normal U for Neuroticism. In Phase D, a new 
activation took place when reaching the baseline since the subject once again thought 
about the effects of methylphenidate. It is necessary to indicate that the Kruskal-Wallis 
test did not show any differences between the records of the three Self-regulation 
Therapy sessions, indicating that they are the equivalent to each other. For this reason 
from among the three Self-regulation Therapy training sessions reproducing the 
methylphenidate effects (R1, R2 and D), for presentation purposes, we chose the data of 
the first session (R1) for the remaining analyses because of the clearer pattern of change 
shown, and because it seemed advisable for us to present the pattern of change of the 
first and closer session after the first 20 mg intake.  
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Figure 3. BFPAL registers (points) for subject 2 for phases A, B, A2 and R1.  
E: Extraversion, N: Neuroticism; A: Agreeableness, R: Responsibility, O: Openness. 
 
 Figure 3 provides the graph of Subject 2’s BFPAL scores records for the four 
experimental conditions: A (baseline), B (20 mg), A (new baseline) and R1 (first 
reproduction of the methylphenidate effects with the Self-regulation Therapy). 
If we compare conditions A and B, the result is similar to that of Subject 1; that 
is, the Big Five personality factors do not display a clear pattern of change for condition 
A, unlike the clear pattern of change observed in condition B (20 mg) with an inverted 
U shape for four of the factors and a normal U shape for Neuroticism. This last factor 
was not noted in Subject 1, which indicates that different patterns of change can be 
obtained. In any case, all the patterns of change observed were very clear. 
 In the third condition (the second baseline of A2), the new baseline displayed 
some differences if compared with the first baseline, mainly a reduction in Neuroticism 
and an increase in Agreeableness. The levels for at least four of the five factors were 
lower than in the first baseline. Our interpretation is that on this day (the second 
baseline) the subject showed less activation. This finding also contrasts with the Phase 
R1 result, where the pattern of change for the Big Five was practically identical to that 
produced for 20 mg of methylphenidate. In other words, although the subject showed 
less activation that day, he was able to reproduce the effects of methylphenidate with 
the same pattern of change. The only difference noted was that the effect brought about 
by the Self-regulation Therapy lasted less than the effect caused by 20 mg of 
methylphenidate, but the intensity of the effect was similar and the pattern of change 
(an inverted U for four factors and a normal U for Neuroticism) was identical. 
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Figure 4. DRD3 expression for Subjects 1 and 2 in phases A, B and C.  
 
 Figure 4 depicts the DRD3 measures for the three phases in both subjects. By 
way of example, we joined Subject 2’s Phases A2 and D to form a single phase which 
we called Phase C. In both cases, we observed a different response pattern between 
Phase A (baseline) and Phases B and C. Thus, while the DRD3 expression showed an 
inverted U shape in Phase A, the opposite occurred in Phases B and C, which showed a 
normal U shape. In comparison to Subject 2, a delay in the gene expression in Phase B 
was noted for Subject 1; that is, it increased during the first hour to lower in the two 
following hours and to once again increase at the end. In Subject 2, a more marked 
reduction was noted. 
Furthermore for Subject 2, we observed that the Self-regulation Therapy proved 
effective to lower the gene expression. We see how the gene expression in Phase C 
increased after the first hour, which also happened in Phase A (baseline). However, 20 
minutes after applying the Self-regulation Therapy, that is, already in the second hour, 
the gene expression clearly lowered and progressively recovered until the baseline at the 
end of the session, which took a similar form, be it less pronounced than in Phase B. 
When comparing both subjects, we saw that the gene expression curves overlapped in 
Phase C. In other words, the DRD3 expression pattern that the Self-regulation Therapy 
produced was similar to that generated by 20 mg of methylphenidate for the same 
subject. 
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Table 1. The Kruskal-Wallis test to Subject 1. 
 
 
 
E: Extraversion, N: Neuroticism; A: Agreeableness,  
R: Responsability, O: Opennes; A: Base-line, B: drug 20 mg, C: drug 40 mg; 
* p < .05; *** p < .001 
  
Big Five Condition  Average 
Rank 
X σ χ2 
E 
A 14.81 8 1.63 
15.53*** B 34.25 17.12 6.87 
C 24.44 12.19 5.79 
N 
A 16.25 7.13 1.4 
8.48* B 28.56 9.56 2.85 
C 28.69 9.44 2.73 
A 
A 11.59 6.19 1.75 
24.1*** B 35.66 15.56 5.98 
C 26.25 10 2.92 
R 
A 13.34 8.06 1.94 
18.79*** B 34.66 16.31 5.67 
C 25.50 11.81 4.23 
O 
A 13.94 8.38 1.45 
16.85*** B 34.09 17.06 6.45 
C 25.47 12.38 5.14 
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Table 2. The Kruskal-Wallis test to Subject 2. 
 
Big Five Condition  Average 
Rank 
X σ χ2 
E 
A1 23.81 10.56 1.54 
14.77** 
B 29.47 14.13 6.42 
A2 7 6.86 1.21 
R1 30.50 13.56 4.82 
N 
A1 34.66 15.38 2.7 
22.71*** 
B 15.88 5.69 6.62 
A2 34.07 15.43 3.86 
R1 14.33 4.67 4.5 
A 
A1 25.69 9.94 0.1 
17.07** 
B 30.78 13.44 6.66 
A2 5.14 2.29 2.13 
R1 26.28 12 6.42 
R 
A1 26.06 14.75 0.68 
18.22*** 
B 31.56 16.19 4.38 
A2 4.93 7.71 1.07 
D 24.39 14 3.35 
O 
A1 21.25 12.38 0.8 
23.44*** 
B 32-69 16.85 5.12 
A2 4.29 8 1.15 
R1 31.44 15.78 4.08 
 
E: Extraversion, N: Neuroticism; A: Agreeableness,  
R: Responsibility, O: Openness; A1: Base-line 1, B: drug 20 mg, A2: Base-line 2,  
R1: Self-regulation therapy; ** p < .01; *** p < .001 
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 In addition to the graphical representation, we did several statistical analyses 
from the single case experimental design perspective (Barlow and Versen, 1984). In 
Tables 1 and 2, the Kruskal-Wallis test results for both subjects and the Big Five factors 
appear; where each experimental condition is taken as a sample. The rank average data, 
as well as the averages and standard deviations of each experimental condition, have 
been added. Significant differences for the different conditions and both subjects’ 
personality factors have been found, and this is the reason why we analyzed the 
differences between conditions in pairs. 
 
Table 3. Two sample Kolmogorov-Smirnov test to subject 1. 
 
Big Five Condition  Z 
E 
A-B 2.12*** 
A-C 2.12*** 
B-C 1.06 
N 
A-B 1.14* 
A-C 1.14* 
B-C 0.35 
A 
A-B 2.12*** 
A-C 2.12*** 
B-C 1.41* 
R 
A-B 1.94** 
A-C 1.94** 
B-C 1.41* 
O 
A-B 2.47*** 
A-C 2.47*** 
B-C 0.09 
 
E: Extraversion, N: Neuroticism; A: Agreeableness,  
R: Responsibility, O: Openness; A: Base-line, B: drug 20 mg, C: drug 40 mg; 
* p < .05; ** p < .01; *** p < .001 
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Table 4. Two sample Kolmogorov-Smirnov test to subject 2. 
 
Big Five Condition  Z 
E 
A1-B 1.41* 
A2-R1 1.76** 
A1-A2 1.93** 
B-R1 0.66 
N 
A1-B 2.29*** 
A2-R1 1.76** 
A1-A2 0.53 
B-R1 0.78 
A 
A1-B 1.41* 
A2-R1 1.54* 
A1-A2 2.2*** 
B-R1 0.58 
R 
A1-B 1.59* 
A2-R1 1.98** 
A1-A2 2.2*** 
B-R1 0.9 
O 
A1-B 1.76** 
A2-R1 1.98** 
A1-A2 2.2*** 
B-R1 0.78 
 
E: Extraversion, N: Neuroticism; A: Agreeableness,  
R: Responsibility, O: Openness; A1: Base-line 1, B: drug 20 mg, A2: Base-line 2,  
R1: Self-regulation therapy; * p < .05; ** p < .01; *** p < .001 
 
 The results of the two sample Kolmogorov-Smirnov tests done with both 
subjects are presented in Tables 3 and 4. Thus for Subject 1 in relation to the baseline 
(A), the Big Five factors scores significantly increased for methylphenidate for both 
condition B (20 mg) and condition C (40 mg), although Neuroticism increased to a 
lesser extent, as observed in Figure 1. However, the Agreeableness and Responsibility 
scores significantly lowered for the 40 mg condition since no significant differences 
were found for the remaining factors. If we observe the averages and standard 
deviations in Table 1, we see how the averages and standard deviations of the scores for 
the other personality factors are lower, except Neuroticism. This is in agreement with 
what we can see in Figure 1, where a 40 mg methylphenidate dose produced the same 
pattern of change for the Big Five factors, but with lower scores. 
 Table 4 provides the results for Subject 2. First of all, the Big Five factors scores 
significantly increased when this subject took 20 mg of methylphenidate (B) if 
compared with the first baseline (A1). Moreover, the same pattern between the scores 
obtained with the Self-regulation Therapy (R1) and the second baseline is observed 
(A2). On the other hand, and save Neuroticism, the Big Five factors scores were 
significantly lower in A2 if compared with A1. This is coherent with that presented in 
Figure 2 as this subject showed less activation in A2 than in A1. Finally, no significant 
differences between conditions B (20 mg) and R1 (Self-regulation Therapy) were been 
obtained, which can be interpreted as them being two equivalent conditions. 
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Discussion  
The results obtained in this study support the hypothesis that the Self-regulation 
Therapy (Amigó, 1992; 1997) reproduces as many patterns of change for the Big Five 
personality factors as the biological ones after one methylphenidate dose. A very similar 
results pattern with EEG and cerebral imaging (SPECT) has been observed with the 
Self-regulation Therapy and the methylphenidate (Amigó, 2005). In addition, a similar 
pattern of change of personality and glutamate concentration in blood has been obtained 
with both methylphenidate intake and the Self-regulation Therapy (Amigó, Caselles, 
Micó & García, 2009). In particular, and as far as the biological effect is concerned, this 
study has verified that the Self-regulation Therapy reproduces the same pattern of 
change (an inverted U) of the DRD3 expression as produced by the stimulating drug. 
   A single case experiment with two voluntary subjects has been conducted. For 
Subject 1, the experiment consisted in three phases, each lasting 4 hours: Phase A 
(baseline), Phase B (20 mg of methylphenidate) and Phase C (40 mg of 
methylphenidate). For Subject 2, the experiment consisted in 4 phases: Phase A1 
(baseline 1), Phase B (20 mg of methylphenidate), Phase A2 (baseline 2) and Phase D 
(Self-regulation Therapy). In all the phases, as many measures from the Big Five 
personality factors were taken as biological measures (the DRD3 expression). In 
addition, Subject 2 underwent three training sessions: one session with a 20 mg 
methylphenidate intake (B2) and two Self-regulation Therapy training sessions (R1 and 
R2). After training, this subject re-applied the Self-regulation Therapy in Phase D. 
 A general factor of activation or personality has been set out which underlies the 
Big Five factors of personality (Musek, 2007). This indicates that a change in the Big 
Five factors can be interpreted as a change in the general level of activation. Along the 
same lines, some research works consider that the general factor of personality can be 
interpreted (Amigó, 2005; Amigó et al., 2008a, Amigó, Caselles & Micó, 2010). These 
authors propose the Unique Personality Trait Theory (UPTT) as a biological mechanism 
to explain the interrelation and pattern of change among the Big Five factors, which is 
based on a balance between tonic general activation, at rest, and phasic activation in 
response to external stimuli such as drugs. 
Thus, the results provided herein also demonstrate that 20 mg of 
methylphenidate (Phase B) produce an intense psychological activation effect on both 
subjects in comparison with the baseline (Phase A). This activation effect takes an 
inverse U shape, meaning that 20 mg of methylphenidate change psychological 
activation in the short term (4 hours) by firstly increasing to descend later (inverted U 
shape). In addition, both subjects modify the DRD3 expression in the same manner if 
compared to the baseline. Therefore, the same dynamic activation pattern produced by 
20 mg of methylphenidate is observed: an inverted U shape for the psychological 
variable (scores in the BFPAL) and a normal U shape for the biological one (the DRD3 
expression). If we consider that the psychological activation measured by the BFPAL 
scores is a state-format version of the Big Five factors or of the general factor of 
personality (Amigó, Micó & Caselles, 2009), we can conclude that 20 mg of 
methylphenidate can modify not only personality in the short term (4 hours), measured 
on scales of adjectives, but also its genetic substratum simultaneously in the same way. 
This result thus confirms the integrated dynamics of the subjective and genetic aspects 
of personality as a response to a stimulating drug. 
 On the other hand, certain evidence for the two-phase effects produced by 
methylphenidate has been obtained on subjective activation by means of the DRD3 
expression. Hence, an increase in the DRD3 expression at one hour after the intake of 
20 mg and of 40 mg of methylphenidate is observed mainly in Subject 1, which lowers 
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over the next two hours and then returns to the baseline during the last hour. This 
pattern of change corresponds to the pattern of change of subjective activation; 
therefore, the subjective activation peak agrees with the minimum activation peak of the 
DRD3 expression. Thus, the higher the methylphenidate concentration in blood (the 
second half of Phase B) or the greater the methylphenidate dose (Phase C), the lower the 
DRD3 expression in relation to the baseline in Subject 1 (Phase A). Subject 2 presents a 
pattern of change in the DRD3 expression in Phase B, which is inverse to that of Subject 
1 during the first two hours. Then a similar, more marked pattern of reduction with a 
subsequent increase in the gene expression is noted during the next two hours. This can 
be interpreted as methylphenidate producing an effect of increased activation in Subject 
2 by progressively reducing the DRD3 expression where the two-phase effect is barely 
perceivable. We can therefore conclude that, for equal doses (20 mg of 
methylphenidate), Subject 1 presents more marked two-phase effects in the DRD3 
expression than Subject 2. 
Methylphenidate increases DRD3 mRNA after the first hour, which subsequently 
lowers progressively at the end of the second and third hours to then return to the 
baseline at the end of the fourth hour. Following the two-phase reactivity hypothesis of 
DRD3, we propose that an initial increase in the low activation condition takes place, 
which is accompanied by a progressive increase in the positive mood. As activation 
increases (a greater dopamine flow in the brain), DRD3 mRNA lowers and, 
consequently, the positive mood diminishes. 
 We also obtained other interesting results. For instance, 40 mg of 
methylphenidate led to a less marked change in personality in Subject 1 (lesser general 
activation) than 20 mg. It is possible that 40 mg of methylphenidate elicit transmarginal 
inhibition. It has been proved that high doses of stimulants produce transmarginal or 
protector inhibition to elude excessive activation (Eysenck, 1967; Gilbert & Hagen, 
1985; Smith, Wilson & Davidson, 1983), producing a lower positive effect and 
increasing negative effects. There is a mathematical model available that predicts this 
mechanism for stimulants based on dose and consumption frequency (Caselles, Micó & 
Amigó, 2011). 
In addition, very similar patterns of change were obtained for both subjects, but 
with different levels of activation, both of which have been recorded by the BFPAL 
scores and by the DRD3 mRNA measurements. This fact shows another relevant aspect 
in personality studies: individual differences. As Figures 1 and 3 illustrate, Subject 1 
was less activated at his baseline than Subject 2 (lower BFPAL scores). Following the 
UPTT, subjects with a lower basal activation level would be more extraverted and 
would display a higher response to stimuli like drugs. Thus, transmarginal inhibition 
would appear earlier in these individuals, as our results corroborate. Finally, a 
mathematical model exists that simulates subjects’ different activation responses as a 
function of their personality (Amigó, Caselles & Micó, 2008a; Caselles, Micó & 
Amigó, 2010). 
 
 This study has clear limitations when it comes to interpreting the biological 
results and personality since it is a study which includes only two subjects. It is 
necessary to extend this study with more regulating genes and a larger number of 
subjects to be able to compare the combined effects of different genes in different 
subjects. However, the single case experimental design with replication presented 
herein is rigorous and allows to put forward the first causal proposals among various 
variables: subjective activation versus biological activation; exciting effects of the 
DRD3 gene expression versus inhibiting effects; subjective and biological effects of a 
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stimulating drug versus biological and the subjective Self-regulation Therapy effects 
which attempts to reproduce the effects of the drug. 
 This it is the first study to state that a subject is able to voluntarily reproduce the 
genetic effects of methylphenidate simultaneously with personality factors. Thus, it is 
possible to voluntarily change, at least temporarily, global personality simultaneously 
with its genetic substratum (the DRD3 expression). Furthermore, the potential 
therapeutic effect of voluntary reproduction from methylphenidate effects has already 
been verified (Amigó, 1997, 2005). This opens up important research and application 
fields, while the possibility of voluntarily changing the expression of a regulating gene 
opens up new and unsuspected possibilities. 
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